Semaglutide, liraglutide, and dulaglutide have all shown to reduce the occurrence of major cardiovascular events like heart attack, stroke, and death in patients with diabetes, while tirzepatide is currently being studied for the same
The information provided here is not a substitute for professional medical advice, diagnosis, or treatment
2C, top)
Selecting the most appropriate GLP-1 receptor agonist requires consideration of multiple patient-specific factors, clinical characteristics, and treatment goals
Bioavailability differs slightly by injection site
Built by Leading Scientists & Engineers A dedicated team of over 60 scientists and engineers is continuously innovating and developing our technology, ensuring it remains at the forefront of personalized health